Combined effect of p53-armed oncolytic virus and immune checkpoint inhibitors in murine pancreatic cancer models

被引：0

作者：

Fujita, Shuto ^{[1
]}

Tazawa, Hiroshi ^{[1
,2
]}

Kajiwara, Yoshinori ^{[1
]}

Kikuchi, Satoru ^{[1
]}

Kuroda, Shinji ^{[1
]}

Noma, Kazuhiro ^{[1
]}

Urata, Yasuo ^{[3
]}

Kagawa, Shunsuke ^{[1
]}

Fujiwara, Toshiyoshi ^{[1
]}

机构：

[1] Okayama Univ, Grad Sch Med, Dept Surg Gastroenterol, Okayama, Japan

[2] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan

[3] Oncolys BioPharma Inc, Tokyo, Japan

来源：

CANCER SCIENCE | 2025年 / 116卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-2182

引用

页码：961 / 961

页数：1

共 46 条

[21] Enhancement of the efficacy of radiofrequency ablation by neoadjuvant oncolytic virus therapy via antitumor immunity and the booster effect of immune checkpoint inhibitors
Yamada, Tomoharu
Inou, Yasushi
Iwai, Miwako
Tateishi, Ryosuke
Koike, Kazuhiko
Todo, Tomoki
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[22] Immune response markers following combination treatment with oncolytic adenovirus AMUN-003 and immune checkpoint inhibitors in a murine model of triple negative breast cancer
Shin, Soon Cheon
Filimon, Beniamin
Yang, Yuefeng
Hu, Zebin
Gadi, Vijayakrishna K.
Xu, Weidong
CANCER RESEARCH, 2023, 83 (07)
[23] Oncolytic Seneca Valley virus (SVV-001) overcomes checkpoint inhibitor resistance and demonstrates a systemic anti-tumor immune response in a syngeneic pancreatic cancer murine model
Hallenbeck, Paul L.
Chada, Sunil
CANCER RESEARCH, 2022, 82 (12)
[24] Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer
Chen, Wanyuan
Fan, Weimin
Ru, Guoqing
Huang, Fang
Lu, Xiaming
Zhang, Xin
Mou, Xiaozhou
Wang, Shibing
ONCOLOGY REPORTS, 2019, 41 (01) : 67 - 76
[25] Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer
Rittner, Karola
Remy-Ziller, Christelle
Hortelano, Julie
Farine, Isabelle
de Meyer, Micael
Nourtier, Virginie
Gantzer, Murielle
Thioudellet, Christine
Slos, Philippe
Preville, Xavier
CANCER RESEARCH, 2015, 75
[26] Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer
McGray, A. J. Robert
Huang, Ruea-Yea
Battaglia, Sebastiano
Eppolito, Cheryl
Miliotto, Anthony
Stephenson, Kyle B.
Lugade, Amit A.
Webster, Gill
Lichty, Brian D.
Seshadri, Mukund
Kozbor, Danuta
Odunsi, Kunle
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[27] Combined treatment with immune checkpoint inhibitors and axitinib against murine renal cell cancer expressing human CA9
Harada, Mamoru
Iida, Yuichi
Komohara, Yoshihiro
Kotani, Hitoshi
CANCER SCIENCE, 2022, 113 : 1425 - 1425
[28] VOYAGER V1 (VV1) ONCOLYTIC VIRUS COMBINED WITH IMMUNE CHECKPOINT THERAPY BOOSTS CTL RESPONSES TO MULTIPLE TUMOR ANTIGENS AND CORRESPONDINGLY DEEPENS TUMOR RESPONSES IN MURINE MODELS OF MELANOMA, LUNG AND COLON CANCER
Ram, Priyanka
Tung, Navpreet
Sharma, Himani
Fulton, Ben
Peng, Kah-Whye
Russell, Stephen
Mohrs, Markus
Thurston, Gavin
Kyratsous, Christos
Baum, Alina
Kirshner, Jessica
Lin, John
Dadi-Mehmetaj, Saida
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A890 - A890
[29] Oncolytic virus therapy as a powerful promoter of a combined tumor antigen specific Th1 cell and immune checkpoint inhibitor-based cancer immunotherapy
Stowbur, D.
Berchtold, S.
Schoerg, B. F.
Beil, J.
Sonanini, D.
Gonzalez-Menendez, I.
Reischl, G.
Ehrlichmann, W.
Beck, R.
Quintanilla-Martinez, L.
Roecken, M.
Pichler, B. J.
Lauer, U. M.
Kneilling, M.
EXPERIMENTAL DERMATOLOGY, 2022, 31 (02) : E109 - E110
[30] Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47A and immune checkpoint inhibitors
Yamada, Tomoharu
Tateishi, Ryosuke
Iwai, Miwako
Tanaka, Minoru
Ijichi, Hideaki
Sano, Makoto
Koike, Kazuhiko
Todo, Tomoki
MOLECULAR THERAPY-ONCOLYTICS, 2023, 28 : 31 - 43

← 1 2 3 4 5 →